The research is getting much better, still a lot of red tape. CARA pharmy is a new up and comer. I'm an investor, so may be biased...but:

Cara Therapeutics doesn't have any products on the market yet, so the company's financial position isn't as solid as the other two on our list. And while Cara's pipeline includes cannabis-based research, the company's future isn't as tightly linked to the medical marijuana industry as either GW Pharmaceuticals or Insys.

Pain medication CR845 is Cara's lead candidate. The company expects to report results from a late-stage clinical study of the kappa opioid receptor drug in treating post-operative pain in the first half of 2017. The potential for CR845 is great, because the drug can relieve pain without causing the addictive qualities associated with many existing opioid drugs.
https://www.fool.com/investing/general/2015/07/10/3-marijuana-stocks-to-watch.aspx